Objective: Extensive studies have shown that ERS may be implicated in the pathogenesis of DCM. We explored the therapeutic effects of lncRNAH19 on DCM and its effect on ERS-associated cardiomyocyte apoptosis. Methods: C57/BL-6j mice were randomly divided into 3 groups: non-DM group (controls), DM group (DCM), and lncRNAH19 overexpression group (DCM+H19 group). The effect of H19 on cardiac function was detected. The effect of H19 on cardiomyocyte apoptosis and cardiac fibrosis in DM was examined. Differentially expressed genes (DEGs) and activated pathways were examined by bioinformatics analysis. STRING database was applied to construct a PPI network using Cytoscape software. The expression of p-PERK, p-IRE1, ATF6, CHOP, cleaved caspase-3, -9, -12 and BAX proteins in cardiac tissue was used to determine the ERS-associated apoptotic indicators. We established the HG-stimulated inflammatory cell model. The expression of p-PERK and CHOP in HL-1 cells following HG was determined by immunofluorescence labeling. The effects of H19 on ERS and PI3K/AKT/mTOR pathway were also detected. Results: H19 improved left ventricular dysfunction in DM. H19 could reduce cardiomyocytes apoptosis and improve fibrosis in vivo . H19 could reduce the expression of p-PERK, p-IRE1α, ATF6, CHOP, cleaved caspase-3, cleaved caspase-9, cleaved caspase-12, and BAX proteins in cardiac tissues. Furthermore, H19 repressed oxidative stress, ERS and apoptosis in vitro . Moreover, the effect of H19 on ERS-associated apoptosis might be rescued by LY294002 (the specific inhibitor for PI3K and AKT). Conclusion: H19 attenuates DCM in DM and ROS, ERS-induced cardiomyocyte apoptosis, which is associated with the activation of PI3K/AKT/mTOR signaling pathway.
Background Metachronous carcinoma presenting as a cardiac malignancy is rare, and timely diagnosis is critical. We report a patient with a primary cardiac tumor who eventually died and performed an imaging-related literature review. Case presentation A 68-year-old Chinese male patient, who had suffered from multiple malignancies, was suddenly found to have severely reduced platelets and symptoms of decreased cardiac function. After undergoing a series of imaging examinations such as transthoracic echocardiography and positron emission tomography-computed tomography, he was found to have a large occupancy within the right heart and was finally diagnosed with a primary cardiac malignancy. Combined with the patient's previous medical history, it was judged that this time it was a metachronous carcinoma. The patient was unable to accept the risk of surgery and eventually died. Conclusion This is a case report reporting a cardiac malignancy. This case highlights the importance of using multiple imaging modalities to make a common diagnosis and the need for more detailed evaluation in patients with metachronous carcinoma.
Background Coronary heart disease (CHD) is a major disease threatening human life and health. Psycho-cardiology diseases aggravate not only the burden of finance but also the progression of CHD. Nowadays, a growing chorus of cardiovascular experts have come to call for an emphasis on the prevention and control of psycho-cardiology. Due to intricate adverse effects of antidepressants, it is urgent to explore a safe and effective early intervention method for psycho-cardiology diseases. Our medical team sought help from traditional Chinese medicine (TCM) and planned to explore the use of QSTMAS herbal paste in the treatment of CHD patients with Qi deficiency and blood stasis syndrome combined with depression and/or anxiety. Methods The single-blind, single-center, randomized controlled trial is designed to recruit 99 patients from China-Japan Friendship Hospital. All patients will be randomly assigned in a 1:2 radio. Both groups will receive standard western medicine treatment for CHD. The test group 2 will be treated with an additional 30ml QSTMAS herbal paste, orally twice daily for up to 12 weeks. The primary endpoints of the study are the changes in GAD-7 and PHQ-9 scores before and after the 12 weeks of intervention. The secondary endpoints included the clinical efficacy of TCM Syndromes of CHD, 6-minute walking test (6MWT), ISI Sleep Scale, laboratory tests, and examinations of the two groups before and after the 12 weeks intervention. Discussion QSTMAS herbal paste is a potential and promising treatment option for the treatment of mild and moderate psychological disorders in the cardiology department. The strict trial design will ensure the objective and scientific evaluation of the clinical efficacy and safety of the combination of QSTMAS herbal paste and standard western medicine in the treatment of CHD patients with Qi deficiency and blood stasis syndrome combined with depression and/or anxiety. Trial registration: China Clinical Trial Registry, ChiCTR2200065179, Version 2.0, Registered on 31 October 2022. http://www.chictr.org.cn/listbycreater.aspx.
SHP-2 is a pervasively Src homology 2 (SH2) domain-containing protein tyrosine phosphatase (PTP) and its specific deletion in macrophages can promote the IL-6 secretion in the pathophysiological process of cardiac hypertrophy. To elucidate the mechanism, AngII infused Lyz-2-Cre/SHP-2flox/flox mice and SHP-2 MφCKO wild-type (SHP-2+/+) mice were subjected to transverse aortic constriction (TAC) to induce cardiac hypertrophy. Echocardiographic scans showed that left ventricular (LV) end-diastolic dimension and left ventricular systolic volume were significantly increased in SHP-2flox/flox group, implying that TAC-induced SHP-2flox/flox can induce LV hypertrophy and damage cardiac function. In addition, IHC analysis and Western blotting demonstrated that SHP-2flox/flox obviously elevated the expression of α-SMA, collagen, circulating macrophage numbers and positive areas and expression level of IL-6 in vitro. Moreover, SHP-2flox/flox positively regulated IRE1α-XBP-1 activation, whereas the expression levels of NF-κB did not differ between SHP-2flox/flox and SHP-2+/+ mice. It was also confirmed that the increased expression levels of IL-6, p-IRE1α, and XBP1s in SHP-2flox/flox mice were markedly reversed by 3,6-DMAD hydrochloride (an inhibitor of the IRE1α-XBP1s pathway). These results demonstrated that SHP-2flox/flox promotes IL-6 secretion via the IRE1α-XBP1s pathway rather than NF-κB signaling pathway in the development of cardiac hypertrophy.
IntroductionMany causes lead to sympathetic-vagus imbalance, which promotes the development of hypertension and accelerates the process of target organ damage. Many studies have shown that exercise training and heart rate variability (HRV) biofeedback can improve diseases caused by autonomic nerve dysfunction, such as hypertension. Based on these theories and the Yin-Yang balance theory of traditional Chinese medicine and Cannon’s homeostasis theory, we have developed an assessment system of autonomic nerve regulation system and a harmony instrument. In this study, we aimed to find a new way to control blood pressure of hypertensive patients via cardiopulmonary resonance indices-based respiratory feedback training.Methods and analysisThis is a prospective, randomised, parallel-controlled clinical trial, which aims to evaluate the effectiveness and safety of biofeedback therapy and exercise rehabilitation combined intervention in hypertension management. 176 healthy individuals will be recruited to get their autonomic nerve function parameters as normal control, while 352 hypertensive patients will be enrolled and randomly divided into a conventional treatment group and an experiment group in a ratio of 1:1. All patients will continue to receive standard hypertension blood pressure treatment, except that patients in the experiment group will have to complete additional daily respiratory training for 6 months. The primary outcome is the difference of clinical systolic blood pressure (SBP) between the two groups after 6 months of intervention. The secondary outcomes include the changes in the mean SBP and diastolic blood pressure (DBP) by 24-hour blood pressure monitoring, home SBP, clinical and home DBP, clinical and home heart rate, the standard-reaching rate of clinic and home SBP and the incidence of composite endpoint events at 6 months.Ethics and disseminationThis study has been approved by the clinical research ethics committee of China-Japan Friendship Hospital (No. 2018-132 K98-2), the results of this study will be disseminated via peer-reviewed publications or conference presentations.Trial registration numberChinese Clinical Trial Registry, ChiCTR1800019457, registered on 12 August 2018.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.